Infectious Enteritis Treatment Market Analysis

Based on drug type, the market is categorized into antibiotics, antiparasitics, anti-spasmodics, and other drug types. The antibiotics segment is anticipated to acquire the largest market share and sustain its dominance to reach USD 388.5 million by end of 2032.

• Antibiotic medications combating bacterial infections, effectively target various enteric infections in adults such as shigellosis, salmonellosis, typhoid fever, and cholera, and will spur the segmental growth. For instance, according to an article published by the National Library of Medicine, in April 2021, acute gastroenteritis stands as one of the most prevalent bacterial infectious diseases globally, with several infections causing significant morbidity. Thus, with the rise in bacterial enteritis cases, there is a corresponding surge in demand for antibiotics, thereby fostering the market growth.

Based on route of administration, the infectious enteritis treatment market is classified into oral and injectable. The oral route segment is projected to hold the largest market share of 71.8% in 2023 and is expected to maintain dominance throughout the analysis period.

• Oral medications play a critical role in combating the infection and managing associated symptoms. Oral antibiotics are often prescribed to target the specific bacterial strains responsible for the enteritis, aiming to eradicate the infection and alleviate symptoms such as diarrhea and abdominal discomfort.

   

• Also, antidiarrheal agents, such as loperamide or bismuth subsalicylate, may also be administered orally to alleviate diarrhea symptoms and improve patient comfort.

   

• Thus, availability of several oral medications in the market to treat infectious enteritis will spur the industry growth.

   

Based on the medication drug type, the infectious enteritis treatment market is bifurcated into branded and generics. The branded segment accounted for USD 295.9 million in 2023 and is expected to account for USD 498.6 million by 2032.

• The branded segment has emerged as the dominant force often backed by extensive research and development efforts, carry a reputation for efficacy and safety. Also, healthcare providers and patients tend to prefer branded treatments due to their perceived higher quality and reliability. This preference, coupled with effective marketing strategies, has propelled the branded segment to prominence in the enteritis treatment landscape.

   

Based on the distribution channel, the infectious enteritis treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment accounted for the largest share of the market and is expected to exhibit 6.1% CAGR between 2024 – 2032 period.

• Hospital pharmacies play a pivotal role in dispensing medications for acute illnesses including enteritis, ensuring timely access to treatment. Also, the pharmacies often stock a wide range of medications, including antibiotics and other therapeutics for enteritis management. This comprehensive availability, combined with the expertise of hospital pharmacists, has led to the segment's prominence in the market.

U.S. dominated the North American infectious enteritis treatment market accounting for the highest market revenue of 167.9 million in 2023 and is expected to show significant growth over the analysis period.

• Favorable regulatory frameworks, coupled with the introduction of advanced products by market players as well as increased investments by pharmaceutical companies are expected to propel regional the regional market growth in the forecast period.

   

• Also, growing awareness about the importance of early infectious disease diagnosis and treatment, coupled with advancements in diagnostic technologies and treatment modalities, encourages individuals to seek medical care. As a result, there is a rising demand for effective treatments and therapies to manage and alleviate symptoms of infectious enteritis, thereby supplementing the market growth.

   

The Asia Pacific infectious enteritis treatment market is poised for rapid growth with a CAGR of 6.7% during the forecast period.

• The Asia Pacific region is poised for significant growth in the market due to factors such as rapid urbanization, increasing healthcare expenditure, and expanding access to healthcare services. Also, rising incidences of enteric infections in the region, coupled with government initiatives to improve healthcare infrastructure and promote research and development, further bolster market expansion prospects in the Asia Pacific.